Investment Rating - The industry investment rating is "In-Line" [8] Core Insights - Secondary home prices in major cities experienced a faster month-on-month decline of 1.7% in April, with a year-on-year drop of 9.9% across approximately 50 tracked cities [2] - 82% of the cities reported month-on-month price decreases, indicating a broad market weakness [2][19] - Total listings increased by 2.1% month-on-month in April, with over 80% of cities having higher listings compared to pre-easing levels in September 2024 [3] - Visitations to agent shops decreased by 16% month-on-month but increased by 19% year-on-year, suggesting a seasonal effect [4][20] - The report anticipates further declines in home prices and sales in May and June, potentially delaying market recovery by 6-12 months [5] - The report recommends a defensive and selective approach, focusing on state-owned enterprises (SOEs) with good visibility [6] Summary by Sections Market Performance - Secondary listing prices fell by 2.0% month-on-month in April, marking the fastest decline since 2022, with 91% of sample cities recording downward adjustments [2][18][14] - The overall sentiment in the market is weakening, with expectations of a 5-10% year-on-year decline in secondary sales volume in the second quarter [4] Listings and Transactions - New secondary listings decreased by 14% month-on-month, while total listings continued to rise, indicating a shift in market dynamics [3] - The report highlights that 86% of the sample cities recorded month-on-month increases in total listings, despite a decline in new listings [3] Recommendations - The report suggests two alpha ideas: 1. Consumption beneficiaries with re-rating potential, such as CR Land (1109.HK) and CR Mixc (1209.HK) [6] 2. High dividend yield companies with good visibility, including C&D (1908.HK) and Greentown Management (9979.HK) [6]

Investment Rating - The report indicates a cautious outlook for the Chinese economy, with expectations of a GDP growth slowdown of 1 percentage point in Q2 2025 due to high tariffs and insufficient policy support [1][2]. Core Insights - The report emphasizes that the high level of tariffs has limited further increases, and the focus of policy responses will gradually shift from investment in emerging industries and urban renewal to consumer spending in the medium term [1][2]. - It is anticipated that the actual GDP growth rate will slow to below 4.5% in Q2 2025, down from 5.4% in Q1 2025, primarily due to the impact of tariffs and moderate policy responses [15][16]. Summary by Sections Tariff Assumptions - The report posits that while tariffs may decrease, they will remain at high levels, with the effective tariff rate expected to stabilize around 45% [2][6]. - If tariffs remain at current levels, the GDP growth forecast for the year could decline by an additional 0.5 percentage points [2][12]. Policy Expectations - The report outlines that the policy response will be moderate, with a focus on supply-side measures rather than aggressive stimulus, reflecting a cautious approach by policymakers [14][15]. - There is an acknowledgment of the need for a shift towards consumer-oriented policies, but uncertainties regarding their multiplier effects are causing hesitation in implementation [14][15]. Economic Projections - The report forecasts that the actual GDP growth rate will further decline to 3.7% by Q4 2025, with nominal GDP growth expected to fall below 3% [16][17]. - The anticipated economic slowdown is attributed to the cumulative effects of high tariffs and the gradual implementation of supportive policies [15][16].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - China's real GDP grew by 5.4% year-on-year in 1Q, with a solid quarterly expansion of 6.6% seasonally adjusted annual rate (saar) [1] - March activity data exceeded expectations, with industrial production rising 7.7% year-on-year and retail sales increasing by 5.9% year-on-year [1] - The report highlights a significant rebound in March exports, which grew by 10.1% month-on-month saar, attributed to front-loaded exports ahead of tariff increases [1] - The average US tariff on China has reached 110%, which is expected to reduce China's growth by 3 percentage points in a static analysis [1] - Leading indicators show a decline in manufacturing PMIs in April, indicating the initial impact of tariffs on new orders and export orders [1] - The report anticipates a deceleration in growth to 1.6% saar in 2Q and 0.4% saar in 3Q due to external risks and tariff impacts [1] Summary by Sections Key Economic Statistics - China's nominal GDP for 2024 is projected at USD 18,160 billion, with real GDP growth rates forecasted at 5.2% for 2023, 5.0% for 2024, and 4.1% for 2025 [8] - Consumer prices in China are expected to remain low, with projections of 0.2% for 2023 and -0.3% for 2025 [8] Recent Policy Measures - The report outlines a two-step policy response approach, with immediate measures focusing on faster deployment of approved options and potential additional fiscal stimulus around July [1] - The first stage includes rapid issuance of government bonds and monetary easing, while the second stage may introduce 1 trillion yuan in additional central government bonds [1] Manufacturing and Industrial Activity - The manufacturing PMI declined in April, indicating a contraction in new orders and export orders, which may lead to weaker production and higher unemployment [1] - High-frequency data shows a 40% drop in container shipping to the US in April, suggesting a shift towards transshipment strategies [1]

Investment Rating - The report maintains an iron ore price forecast of $100/t for 2025, indicating a stable outlook amidst global economic challenges [1][5][14]. Core Insights - Global steel output has started the year relatively flat, with a decrease of 0.4% in Q1 2025, driven by a 1.7% decline in the Rest of the World (RoW) while China saw a slight increase of 0.6% [1][4][11]. - The forecast for global steel production in 2025 has been revised down from a growth of 20 million tons (Mt) to a decline of 5 Mt, primarily due to reduced expectations for RoW production [1][4][14]. - Iron ore supply has faced disruptions due to severe weather conditions in Australia, leading to a reduction of 10 Mt in Australian supply forecasts for 2025 [1][4][28]. - Despite these challenges, iron ore prices have shown resilience, remaining near $100/t, with only slight fluctuations following tariff announcements [1][4][5]. Summary by Sections Global Steel Production - Global steel output is down 0.4% year-to-date (YTD) in Q1 2025, with China showing a positive trend in April [4][19]. - The report anticipates a contraction in crude steel production in China by 1.5% in 2025, with a total output forecast of 990 Mt [7][8][14]. Iron Ore Supply and Demand - Iron ore supply disruptions in Q1 2025 have led to a significant decrease in Australian production forecasts, with China’s port stocks adjusting to meet demand [1][4][11]. - The report highlights a balanced supply-demand scenario, with iron ore prices expected to remain stable at $100/t due to cost curve support and an unchanged outlook for China [1][5][28]. Price Forecasts - The price forecast for iron ore remains unchanged at $100/t for 2025, reflecting a stable market despite external economic pressures [5][14][28]. - The report notes that the medium-term outlook may see a loosening of supply-demand dynamics as new projects come online, particularly from Simandou starting in Q2 2026 [5][28].

Investment Ratings - Integra LifeSciences (IART): Underweight [4] - Inspire Medical (INSP): Overweight [4] - Insulet Corp (PODD): Overweight [4] - Enovis (ENOV): Neutral [4] - Haemonetics (HAE): Overweight [4] - TransMedics Group (TMDX): Neutral [4] - Zimmer Biomet (ZBH): Overweight [4] Core Insights - The MedTech sector is experiencing mixed earnings reports, with several companies expected to beat or miss their earnings estimates [1] - Integra LifeSciences faces challenges due to ongoing operational issues, limiting its ability to offset higher component costs and tariffs, leading to a downward revision in EPS guidance [4] - Inspire Medical has a strong track record of beating revenue expectations and is expected to continue this trend, with a focus on the launch of Inspire 5 [5][7] - Insulet Corp has pre-announced a top-line beat and guidance raise, indicating strong performance in new patient starts and international rollout of Omnipod 5 [14][17] - Enovis is expected to deliver modest upside in earnings, supported by positive market trends in orthopedics [11][12] - Haemonetics is projected to outperform on margins and adjusted EPS, driven by a favorable product mix and cost leverage [15] - TransMedics is anticipated to report strong growth in organ transplant volumes, with limited exposure to macroeconomic challenges [20][22] Company Summaries Integra LifeSciences (IART) - Historical performance shows a 55% beat rate on top-line and 73% on bottom-line, with an average EPS beat of $0.05 [2] - Expected sales of $381.2 million, reflecting a 4.5% organic decline, with EPS forecasted at $0.43 [4] Inspire Medical (INSP) - Historical performance indicates an 85% beat rate on top-line and a 74% positive stock reaction [5] - Anticipated strong performance in new patient starts and potential upside in EPS due to better gross margins [17] Insulet Corp (PODD) - Historical performance shows a 93% beat rate on top-line and a mixed stock reaction [14] - Expected to raise full-year guidance following a strong quarter, with EPS forecasted at $0.86 [17] Enovis (ENOV) - Historical performance indicates a 48% beat rate on top-line and a 90% on bottom-line [10] - Expected sales of $558.2 million, with EPS forecasted at $0.76, reflecting a positive outlook in orthopedics [12] Haemonetics (HAE) - Historical performance shows a 61% beat rate on top-line and 85% on bottom-line [13] - Forecasted adjusted EPS of $1.24, driven by improved margins and a favorable product mix [15] TransMedics Group (TMDX) - Historical performance indicates an 83% revenue beat rate, with shares showing volatility post-earnings [18] - Expected sales growth of 28%, with a focus on strong demand in organ transplant procedures [20][22] Zimmer Biomet (ZBH) - Historical performance shows a 59% beat rate on revenues and 82% on earnings [6] - Anticipated revenue of $194 million, with a focus on maintaining growth despite macroeconomic challenges [7]

Investment Rating - Industry View: In-Line [5] Core Insights - Urea prices have increased significantly, with US NoLa urea prices rising by $36/st to $440-552/st fob WoW, driven by potential Chinese export resumption and strong domestic demand [1] - Potash prices have seen modest increases, with SE-Asia MOP prices up by $5/t to $335-355/t cfr WoW, while US NoLa MOP prices rose by $2/st to $315-320/st fob [2] - Phosphate prices remained largely unchanged, although select markets are experiencing upward price pressure due to changes in Indian pricing policies and potential updates on Chinese phosphate fertilizer exports [3] Summary by Sections Urea Market - China is expected to resume urea exports in May, with a projected export quota of 3-4 million tons for 2025, while US prices have jumped significantly [1] - Brazilian urea prices increased by $13/t to $390-415/t cfr, reflecting a shift in market dynamics post-China news [1] Potash Market - Potash prices in SE-Asia rose by $5/t to $335-355/t cfr, while US NoLa prices increased by $2/st to $315-320/st fob, indicating stable demand despite a quiet market [2] - Chinese port inventories have dropped below 2 million tons, prompting expectations for new contract settlements [2] Phosphate Market - Most global DAP/MAP benchmarks remained stable, but Indian players are expected to increase activity in the market following the reversal of a price ceiling [3] - Updates on Chinese phosphate fertilizer exports are anticipated, with discussions on DAP/MAP export quota allocations expected to follow the Chinese Labor Day holiday [3] Soy Crush Dynamics - Brazil's soy harvest is 94.8% complete, ahead of last year's pace, while Argentina's harvest is lagging at 23.6% complete [9] - US soybean planting is at a record 18% complete, with the EPA issuing an emergency waiver for E15 sales during the summer driving season [9] - Global soy crush margins have mostly increased, with US margins rising to $1.33/bu, driven by lower input costs [10]

Investment Rating - The report rates Tesla Inc as a "Top Pick" with an "Overweight" stock rating and an "In-Line" industry view [6][77]. Core Insights - The relationship between AI and manufacturing is essential for the revival of US manufacturing, with AI acting as both a cause and an effect [1][2]. - Tesla's competitive advantage is attributed to a combination of six key attributes, with manufacturing being the most critical component [9][11]. - The report emphasizes that manufacturing is no longer solely about low costs but is increasingly focused on technology and innovation [2]. Summary by Sections Investment Overview - Price target for Tesla is set at $410.00, with the current price at $280.26 and a market cap of approximately $986.8 billion [6]. Industry Context - The report discusses the importance of reshoring manufacturing due to AI diffusion, highlighting that advanced factories are integral to future manufacturing capabilities [1][2]. Competitive Advantages - Tesla's unique attributes include data collection from over 7 million cars, in-house robotics, leading energy solutions, a world-class AI team, and a highly integrated manufacturing process [11][10]. - The report draws parallels between Tesla and Amazon, suggesting that Tesla's vehicle manufacturing serves as a platform for broader technological advancements [12][10].

Investment Rating - The report maintains a reactive and supply-centric policy stance, indicating a cautious outlook on real GDP growth, projecting a deceleration to below 4.5% year-on-year in Q2 and below 4% in Q3, compared to 5.4% in Q1 [1] Core Insights - The People's Bank of China (PBoC) has introduced a new round of monetary easing, slightly exceeding market expectations, to bolster domestic market confidence ahead of US-China negotiations [1] - Key measures include a 50 basis point cut in the reserve requirement ratio (RRR), releasing Rmb1 trillion in long-term liquidity, and a 10 basis point cut in the policy rate to 1.4% [3] - A total of Rmb1.1 trillion in relending quota has been allocated, with specific quotas for service consumption, elderly care, sci-tech innovation, agriculture, and small businesses [3] - The report anticipates a supplementary fiscal package of Rmb1-1.5 trillion to be announced in the second half of the year [1] Summary by Sections Monetary Policy Measures - The PBoC's measures include a 50 basis point RRR cut, releasing Rmb1 trillion in liquidity [3] - A 10 basis point reduction in the policy rate to 1.4% and a 25 basis point cut for structural monetary policy tools [3] - An increase in relending quotas, with Rmb500 billion for service consumption and elderly care, Rmb300 billion for sci-tech innovation, and Rmb300 billion for agriculture and small businesses [3] Economic Outlook - The report projects a rapid deceleration in real GDP growth to below 4.5% in Q2 and below 4% in Q3, down from 5.4% in Q1 [1] - The overall policy stance remains reactive and supply-centric, which may only partially mitigate tariff shocks [1]

Investment Rating - The industry view is rated as In-Line [8] Core Insights - The report maintains a conservative stance on cloud semiconductors in the near term, with expectations that the cycle could trough in the second half of 2025 [2][6] - A recent CIO survey indicates potential downside for China cloud capital expenditures (capex) in 2H25, with data center build-out being a top spending priority but also the most likely to face budget cuts [3][11][15] - Strong orders for non-AI cloud semiconductors are anticipated into 2Q25, with Montage Technology showing sequential revenue growth [4][6] - AI cloud semiconductors may experience a slowdown in specification migration, but demand remains strong for inference applications, particularly for Nvidia [5][10] Summary by Sections Cloud Semiconductors - The report suggests that the cloud semiconductor market is heading into a trough in 2H25, with a conservative outlook maintained for the near term [2][10] - The top four cloud service providers (CSPs) reported a 64% year-over-year increase in capex in 1Q25, slightly down from 68% [6][30] CIO Survey Insights - The CIO survey indicates that data center build-out is a top priority for spending in 2025, but it is also the category most vulnerable to cuts, with a 19% response rate indicating it is likely to be cut, increasing to 29% after the announcement of reciprocal tariffs [3][18] - The defensiveness of data center build-out has decreased significantly post-tariff announcements [18] Company-Specific Insights - Montage Technology's price target has been adjusted from RMB 90.00 to RMB 88.00, reflecting earnings estimate cuts due to uncertainties in the market [8][45] - The report anticipates a 38% year-over-year growth in global cloud capex for 2025, up from a previous forecast of 31%, indicating strong investment trends among major cloud players [19][24] Financial Projections - Earnings estimates for Montage have been revised downwards, with a 2% cut for 2025 and a 5% cut for 2026, reflecting risks associated with potential cuts in data center projects [45][46] - The financial summary for Montage indicates projected net sales of RMB 5.601 billion for 2025, with a gross profit margin of 60.6% [41][46]

Investment Rating - The report maintains a cautious outlook on the US-China trade relationship, expecting gradual tariff de-escalation but with elevated tariffs remaining in place [2][3]. Core Insights - The report anticipates that the US and China will initiate trade talks soon, leading to a phased reduction in tariffs, although the effective tariffs on China will remain high at 45% by year-end [2][3]. - China's real GDP growth is projected to decline from 5.4% year-on-year in Q4 2024 to 3.7% year-on-year in Q4 2025, with the peak impact of tariffs expected in Q2 2025 [3]. Summary by Sections - **Trade Talks**: Vice Premier He Lifeng will meet with US Treasury Secretary Scott Bessent, marking the first high-level talks since recent tariff escalations [1]. - **Tariff Projections**: Current US effective tariffs on China are at 107%, expected to decrease to 45% by the end of 2025, indicating a significant reduction but still at elevated levels [2]. - **Economic Impact**: The report highlights a full percentage point dip in China's GDP year-on-year due to tariff impacts, with the most significant effects felt in Q2 2025 [3].